CSAClinical-Stage Asset Intelligence
Catalyst calendar Get the data
Home / Pfizer INC (PFE) / elranatamab
Forward catalyst · PFE

elranatamab

Sponsor Pfizer INC · listed as PFE

READOUT Phase 3 Confidence: medium Source: clinicaltrials

elranatamab is a clinical-stage drug asset sponsored by Pfizer INC, listed as PFE. CSA tracks 2 forward catalysts for it — the nearest is a readout expected Aug 30, 2026 (day precision, medium confidence), tied to trial NCT06152575. The asset is in Phase 3 and currently recruiting, studied in Multiple Myeloma. It appears across 6 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT
Expected date2026-08-30
As disclosedAug 30, 2026
Date precisionday
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT06152575
PhasePHASE3
StatusRECRUITING
Lead sponsorPfizer
Listed asPFE
Condition(s)Multiple Myeloma

All tracked catalysts for elranatamab

DateEventConfidenceTrial
2026-08-30READOUTmediumNCT06152575
2027-08-04READOUTmediumNCT05317416
!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 →   More PFE catalysts